AI Article Synopsis
- Meningococcal serogroup B (MenB) vaccination with the 4CMenB vaccine was tested for its effectiveness and safety among 3,651 healthy participants aged 10 to 25, using different dosing schedules (0-2, 0-6, and 0-2-6 months).
- The study measured the immune response through two methods: a test-based approach showing high immune breadth (over 78%) and a responder-based approach indicating a significant percentage of participants achieved strong responses (up to 93.4% for the 0-2-6 schedule).
- The results showed no major differences in effectiveness across the dosing schedules, confirming that the simpler 2-dose regimen (0-2)
Article Abstract
Background: Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains.
Methods: In a phase 3 trial, 3651 healthy 10- to 25-year-old participants were randomized 5:5:9:1 to receive 4CMenB (0-6 schedule), 4CMenB (0-2-6 schedule), investigational MenABCWY vaccine, or control MenACWY-CRM vaccine. The primary objectives were to evaluate safety and demonstrate breadth of immune response by enc-hSBA assay against the MenB strain panel using test-based (percentage of samples without bactericidal activity against strains after 4CMenB vs control vaccination) and responder-based (percentage of participants whose postvaccination sera kill ≥70% strains) approaches. Success was demonstrated with 2-sided 97.5% confidence interval (CI) lower limit >65%. Immunogenicity was assessed by traditional hSBA assay against four indicator strains.
Results: Breadth of immune response (test-based) was 78.7% (97.5% CI, 77.2-80.1), 81.8% (80.4-83.1), 83.2% (81.9-84.4) for the 0-2, 0-6, and 0-2-6 schedules, respectively, and (responder-based) 84.8% (81.8-87.5), 89.8% (87.2-92.0), and 93.4% (91.2-95.2), respectively. No clinically relevant differences in immunogenicity were observed across schedules. 4CMenB was well tolerated.
Conclusions: The 2-dose (0-2, 0-6) 4CMenB schedules met predefined criteria for success for both breadth of immune response endpoints against a diverse MenB strain panel, had comparable immunogenicity, and safety in line with the established 4CMenB safety profile. The 3-dose schedule provided no additional immunological benefit, supporting use of the 4CMenB 0-2 schedule.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584413 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An engineered immunogen activates diverse HIV broadly neutralizing antibody precursors and promotes acquisition of improbable mutations.
Sci Transl Med
January 2025
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Elicitation of HIV broadly neutralizing antibodies (bnAbs) by vaccination first requires the activation of diverse precursors, followed by successive boosts that guide these responses to enhanced breadth through the acquisition of somatic mutations. Because HIV bnAbs contain mutations in their B cell receptors (BCRs) that are rarely generated during conventional B cell maturation, HIV vaccine immunogens must robustly engage and expand B cells with BCRs that contain these improbable mutations. Here, we engineered an immunogen that activates diverse precursors of an HIV V3-glycan bnAb and promotes their acquisition of a functionally critical improbable mutation.
View Article and Find Full Text PDFAntigenic Imprinting Dominates Humoral Responses to New Variants of SARS-CoV-2 in a Hamster Model of COVID-19.
Microorganisms
December 2024
KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute, Virology, Antiviral Drug and Vaccine Research Group, Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD), 3000 Leuven, Belgium.
The emergence of SARS-CoV-2 variants escaping immunity challenges the efficacy of current vaccines. Here, we investigated humoral recall responses and vaccine-mediated protection in Syrian hamsters immunized with the third-generation Comirnaty Omicron XBB.1.
View Article and Find Full Text PDFThe growing body of experimental and computational studies suggested that the cross-neutralization antibody activity against Omicron variants may be driven by balance and tradeoff of multiple energetic factors and interaction contributions of the evolving escape hotspots involved in antigenic drift and convergent evolution. However, the dynamic and energetic details quantifying the balance and contribution of these factors, particularly the balancing nature of specific interactions formed by antibodies with the epitope residues remain scarcely characterized. In this study, we performed molecular dynamics simulations, ensemble-based deep mutational scanning of SARS-CoV-2 spike residues and binding free energy computations for two distinct groups of broadly neutralizing antibodies : E1 group (BD55-3152, BD55-3546 and BD5-5840) and F3 group (BD55-3372, BD55-4637 and BD55-5514).
View Article and Find Full Text PDFTypical high-throughput single-cell RNA-sequencing (scRNA-seq) analyses are primarily conducted by (pseudo)alignment, through the lens of annotated gene models, and aimed at detecting differential gene expression. This misses diversity generated by other mechanisms that diversify the transcriptome such as splicing and V(D)J recombination, and is blind to sequences missing from imperfect reference genomes. Here, we present sc-SPLASH, a highly efficient pipeline that extends our SPLASH framework for statistics-first, reference-free discovery to barcoded scRNA-seq (10x Chromium) and spatial transcriptomics (10x Visium); we also provide its optimized module for preprocessing and -mer counting in barcoded data, BKC, as a standalone tool.
View Article and Find Full Text PDFAPhA Foundation Incentive Grants: A Thirty-year descriptive review.
J Am Pharm Assoc (2003)
January 2025
Senior Manager, Communications and Program Engagement, APhA Foundation, Washington, DC.
Objective: The objective of this project was to describe the breakdown of project topics and geographic reach of Incentive Grant funded projects from 1994-2024 and summarize the number of patients or survey respondents reached.
Methods: All available reports and supporting documents for the Incentive Grants program were reviewed using the APhA Foundation internal database. Projects were assigned a geographical region using US Census Bureau Divisions, and categorized using focus areas from grant calls-for-proposals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!